Physiological Effect: Decreased GI Motility
✉ Email this page to a colleague
Drugs with Physiological Effect: Decreased GI Motility
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-001 | Sep 10, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-001 | Sep 10, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xeris | GVOKE KIT | glucagon | SOLUTION;SUBCUTANEOUS | 212097-005 | Aug 20, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-003 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-003 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
